Patients with inflammatory diseases such as rheumatoid arthritis or psoriasis have a higher risk of developing Alzheimer’s disease, which can be reduced by treatment with tumor necrosis factor (TNF) inhibitors. That finding, “Tumor Necrosis Factor (TNF) Blocking Agents Reduce Risk for Alzheimer’s Disease in Patients with Rheumatoid…
A natural compound with antioxidative properties that might help to delay the onset of neurodegenerative diseases like Alzheimer’s can now be produced in baker’s yeast, a study reports. This new way of producing ergothioneine, as the compound is known, may lead to a commercially viable new treatment for people…
A Phase 2b study of oral neflamapimod in treating mild Alzheimer’s disease met its secondary goals of statistically significant drops in phospho-tau and tau protein levels in the cerebrospinal fluid (CSF) of treated patients compared to those given a placebo, EIP Pharma announced. But the trial failed to show evidence of…
Long-term antibiotic treatment, aimed at altering the bacterial population in the gut, was found to reduce the inflammation and amyloid plaque formation that is a hallmark of Alzheimer’s disease — but only in male mice. The same treatment had no effect on female mice, a study found. The…
African-Americans have lower expression of two biomarkers of Alzheimer’s, suggesting a possible race-dependent biological mechanism that contributes to the development of the disease, a study shows. This discrepancy between African-American and white patients is particularly relevant for those who carry the ApoE4 variant of the ApoE gene. The study, “…
Deep learning, a type of artificial intelligence, used brain imaging scans to predict — years in advance and with nearly 100% sensitivity — patients who eventually developed Alzheimer’s disease, a study reports. The study, “A Deep Learning Model to Predict a Diagnosis of Alzheimer Disease by Using 18F-FDG PET of…
Essential oils derived from different plant species have revealed encouraging clinical and preclinical results to reverse cognitive and memory impairments in Alzheimer’s disease, a review study has found. The study, “Essential Oils as Treatment Strategy for Alzheimerʼs Disease: Current and Future Perspectives,” was published in the journal…
High levels of free triiodothyronine — a type of thyroid hormone — are associated with a lower rate of Alzheimer’s disease risk in patients who have subjective or objective mild cognitive impairment, a new study shows. The study, “Low serum concentration of free triiodothyronine (FT3) is associated with increased risk of…
A newly developed strategy may help researchers identify which people with mild cognitive impairment are likely to develop Alzheimer’s disease. The study, “Utilizing Semantic Intrusions to Identify Amyloid Positivity in Mild Cognitive Impairment,” was published in the journal Neurology. There is a critical need to develop disease-modifying treatments for Alzheimer’s…
ProMIS Neurosciences’ lead therapeutic candidate for Alzheimer’s disease, PMN310, showed an improved safety profile when directly compared to other amyloid-beta directed antibodies, according to preclinical study results. Unlike BAN2401 (Biogen, Eisai) and aducanumab (Biogen), two amyloid-beta directed antibodies both in clinical development, PMN310 did not…
Get regular updates to your inbox.